Home > Neurology > EAN 2019 > Migraine > Short- and long-term efficacy of erenumab in hard-to-treat patients

Short- and long-term efficacy of erenumab in hard-to-treat patients

Conference
EAN 2019
Trial
LIBERTY, STRIVE
In a hard-to-treat patient population with multiple prior preventive treatment failures, efficacy of erenumab 140 mg was sustained throughout a 24- week period in an open-label extension phase (OLE) of the LIBERTY study [1]. Erenumab also showed sustained efficacy through week 52 in patients with ≥1 prior preventive treatment failures in the STRIVE study [2]. The placebo-controlled LIBERTY study demonstrated efficacy of erenumab 140 mg after 12 weeks in episodic migraine patients with prior preventive treatment failures. The 240 patients completing the double-blind phase were then enrolled into the OLE to receive monthly erenumab 140 mg. Overall, efficacy data over 24 weeks (assessed over weeks 13–16, 17–20, and 21–24) was generally in line with prior erenumab trials. Patients with continuous use of erenumab showed sustained efficacy in all outcomes assessed. Patients who switched from placebo to erenumab in the OLE showed improvement from the first...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on